Understand the source comparison
AOD-9604 Mechanism of Action Detailed: Comparison to Alternatives
AOD-9604 β3-adrenergic agonism β3-adrenergic receptor High (40–60% increase in FFA release) None. No effect on GLUT4 or insulin signaling None. No IGF-1 production 8–12 hours hGH (191aa) GH receptor activation Growth hormone receptor (GHR) High (comparable to
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- AOD-9604
- β3-adrenergic agonism
- β3-adrenergic receptor
- High (40–60% increase in FFA release)
- None. No effect on GLUT4 or insulin signaling
- None. No IGF-1 production
- 8–12 hours
- hGH (191aa)
- GH receptor activation
- Growth hormone receptor (GHR)
- High (comparable to AOD-9604)
- Negative. Suppresses insulin-mediated glucose uptake
- High. Stimulates protein synthesis, bone growth, IGF-1
- 2–4 hours
- CJC-1295
- GHRH analog (stimulates endogenous hGH)
- GHRH receptor
- Moderate (indirect via elevated hGH)
- Negative. Secondary to hGH elevation
- Moderate. Depends on endogenous hGH response
- 6–8 days
- Clenbuterol
- β2-adrenergic agonism
- β2-adrenergic receptor
- High (non-selective adrenergic stimulation)
- Mild negative. Increases hepatic glucose output
- None
- 35 hours
- 5-Amino-1MQ
- NNMT inhibition (increases NAD+ and β-oxidation)
- Nicotinamide N-methyltransferase (NNMT)
- Moderate (indirect metabolic effect)
- None. May improve insulin sensitivity
- 4–6 hours
- Professional Assessment
- AOD-9604 is the only agent in this group that selectively stimulates lipolysis via β3 receptors without affecting glucose metabolism or producing anabolic side effects. It occupies a unique niche: targeted fat mobilization with no hyperglycemia, no cardiac stimulation (unlike clenbuterol), and no IGF-1 elevation (unlike hGH).